KRAS and acute myeloid leukemia: Novel therapeutic avenues are necessary for AML patients harboring KRAS, NRAS and FLT3-ITD mutations (also named activating signaling gene mutations), because they exhibit a relatively unfavorable outcome with VEN-AZA (47).